PE20220807A1 - Nuevos inhibidores de egfr - Google Patents

Nuevos inhibidores de egfr

Info

Publication number
PE20220807A1
PE20220807A1 PE2021002083A PE2021002083A PE20220807A1 PE 20220807 A1 PE20220807 A1 PE 20220807A1 PE 2021002083 A PE2021002083 A PE 2021002083A PE 2021002083 A PE2021002083 A PE 2021002083A PE 20220807 A1 PE20220807 A1 PE 20220807A1
Authority
PE
Peru
Prior art keywords
compounds
refers
egfr inhibitors
new egfr
cancer
Prior art date
Application number
PE2021002083A
Other languages
English (en)
Inventor
Cosimo Dolente
Annick Goergler
David Stephen Hewings
Georg Jaeschke
Bernd Kuhn
Yvonne Alice Nagel
Roger David Norcross
Christa Ulrike Obst-Sander
Antonio Ricci
Daniel Rueher
Sandra Steiner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20220807A1 publication Critical patent/PE20220807A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

Referido a compuestos inhibidores de receptor del factor de crecimiento epidermico (EGFR). Un compuesto seleccionado es 2-(6,7-dihidro-5H-pirrolo[1,2-c]imidazol-1-il)-2-[6-[4-(1-etil-4-piperidil)fenil]-1-oxo-4-(trifluorometil) isoindolin-2-il]-N-tiazol-2-il-acetamida. Tambien se refiere a procedimientos para su preparacion, productos intermedios, formulaciones farmaceuticas que comprenden dichos compuestos, y uso en el tratamiento terapeutico y/o profilactico del cancer, en particular cancer de pulmon no microcitico.
PE2021002083A 2019-06-21 2020-06-19 Nuevos inhibidores de egfr PE20220807A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19181772 2019-06-21
PCT/EP2020/067055 WO2020254546A1 (en) 2019-06-21 2020-06-19 New egfr inhibitors

Publications (1)

Publication Number Publication Date
PE20220807A1 true PE20220807A1 (es) 2022-05-20

Family

ID=67001684

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021002083A PE20220807A1 (es) 2019-06-21 2020-06-19 Nuevos inhibidores de egfr

Country Status (19)

Country Link
US (2) US20220315591A1 (es)
EP (2) EP3986567B1 (es)
JP (2) JP7530390B2 (es)
KR (1) KR20220024096A (es)
CN (2) CN113993591A (es)
AR (2) AR119207A1 (es)
AU (1) AU2020296933A1 (es)
BR (1) BR112021024810A2 (es)
CA (1) CA3139171A1 (es)
CL (1) CL2021003373A1 (es)
CO (1) CO2021016967A2 (es)
CR (1) CR20210614A (es)
IL (1) IL287806A (es)
MA (1) MA56507A (es)
MX (1) MX2021015889A (es)
PE (1) PE20220807A1 (es)
TW (2) TW202115070A (es)
WO (2) WO2020254547A1 (es)
ZA (1) ZA202108775B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3986897T1 (sl) 2019-06-21 2023-12-29 F. Hoffmann-La Roche Ag Inhibitor EGFR za zdravljenje raka
MX2021015889A (es) 2019-06-21 2022-02-03 Hoffmann La Roche Nuevos inhibidores de egfr.
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110212078A1 (en) 2008-06-25 2011-09-01 Reddy Panduranga Adulla P Synthesis and use of heterocyclic antibacterial agents
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
MX2017014550A (es) 2015-05-14 2018-02-26 Wistar Inst Inhibidores del antigeno nuclear epstein-barr 1 (ebna1) y metodos que los utilizan.
CA2987914C (en) * 2015-06-30 2022-09-13 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
WO2018220149A1 (en) * 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Compounds
WO2020002487A1 (en) 2018-06-29 2020-01-02 F. Hoffmann-La Roche Ag Compounds
WO2020254544A1 (en) 2019-06-21 2020-12-24 F. Hoffmann-La Roche Ag New egfr inhibitors
SI3986897T1 (sl) 2019-06-21 2023-12-29 F. Hoffmann-La Roche Ag Inhibitor EGFR za zdravljenje raka
MX2021015889A (es) 2019-06-21 2022-02-03 Hoffmann La Roche Nuevos inhibidores de egfr.

Also Published As

Publication number Publication date
IL287806A (en) 2022-01-01
MX2021015889A (es) 2022-02-03
CO2021016967A2 (es) 2022-01-17
ZA202108775B (en) 2022-09-28
EP3986566A1 (en) 2022-04-27
KR20220024096A (ko) 2022-03-03
CR20210614A (es) 2022-02-11
WO2020254546A1 (en) 2020-12-24
JP7530390B2 (ja) 2024-08-07
EP3986567B1 (en) 2023-08-30
CN113993591A (zh) 2022-01-28
EP3986566B1 (en) 2023-08-30
BR112021024810A2 (pt) 2022-01-25
JP7561779B2 (ja) 2024-10-04
CN113993590A (zh) 2022-01-28
AU2020296933A1 (en) 2021-12-02
US20220112199A1 (en) 2022-04-14
US20220315591A1 (en) 2022-10-06
JP2022537772A (ja) 2022-08-29
AR121167A1 (es) 2022-04-27
EP3986566C0 (en) 2023-08-30
MA56507A (fr) 2022-04-27
EP3986567A1 (en) 2022-04-27
CN113993590B (zh) 2024-08-23
WO2020254547A1 (en) 2020-12-24
TW202115073A (zh) 2021-04-16
CA3139171A1 (en) 2020-12-24
EP3986567C0 (en) 2023-08-30
JP2022537771A (ja) 2022-08-29
AR119207A1 (es) 2021-12-01
TW202115070A (zh) 2021-04-16
CL2021003373A1 (es) 2022-10-07

Similar Documents

Publication Publication Date Title
PE20220807A1 (es) Nuevos inhibidores de egfr
PH12019501350A1 (en) Amino-triazolopyridine compounds and their use in treating cancer
MX2021003517A (es) Composiciones de inhibidor de tirosina quinasa, metodos de fabricacion y metodos de uso.
PH12016502168B1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
CA2925624C (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
NZ771886A (en) Purinone compounds and their use in treating cancer
PH12015501483A1 (en) Heterocyclic compounds and uses thereof
MX347040B (es) Inhibidores de tirosina-cinasas.
PH12018500532A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
CL2011000124A1 (es) Compuestos derivados de 3-aril-4-heterociclil-pirazoles, inhibidores de proteina quinasa b-raf; metodo de inhibicion in vitro de la proteina quinasa b-raf; composicion farmaceutica; producto de combinacion farmaceutica; y su uso para el tratamiento del cancer.
EP2576549A4 (en) Bicyclic Heteroarylkinase Inhibitors and Methods of Use
ZA202205900B (en) 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer
PE20191655A1 (es) Combinaciones farmaceuticas
JO3279B1 (ar) مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز
WO2008059368A3 (en) Fused 2-amino pyrimidine compounds and their use for the treatment of cancer
PH12016502353A1 (en) Pharmaceutical composition
MY192861A (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
WO2014106800A8 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
EP3811946A4 (en) USE OF A CDK4/6 INHIBITOR IN COMBINATION WITH AN EGFR INHIBITOR IN THE PREPARATION OF A MEDICINE FOR THE TREATMENT OF TUMOR DISEASES
CO2022006466A2 (es) Inhibidores de egfr alostéricos y métodos de uso de los mismos
PE20181895A1 (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer
CL2009001112A1 (es) Compuestos derivados de cinolin-3-carboxamida, inhibidores de la quinasa csf-1r; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
MX2019000159A (es) Pirrolo[2,3-d]piridazin-4-onas sustituidas y pirazolo[3,4-d]pirida zin-4-onas como inhibidores de la proteina quinasa.
MX2022001158A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.